Q-omics provides the consensus-scored PCNX3 profile across patient tissues and cancer cell-line models. PCNX3 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PCNX3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PCNX3 RNA expression shows 19,040 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where PCNX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCNX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCNX3 survival associations across molecular data types. PCNX3 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCNX3 RNA expression–survival associations across cancer types. High PCNX3 expression shows unfavorable associations in ACC, LIHC, KICH, MESO, KIRC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PCNX3 RNA expression.
This table summarizes PCNX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PCNX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCNX3 shows higher tumor expression in HNSC, KIRP, LIHC, BLCA, LUAD and STAD. The HNSC box plot shows higher PCNX3 RNA expression in tumor versus normal tissue (log2 FC = +1.193, t-test p < 0.001).
This table shows molecular features associated with PCNX3 in patient tissues and cancer cell lines. In patient samples, PCNX3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCNX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
